	US 11,697,677 B2
	Chimeric molecules providing targeted costimulation for adoptive cell therapy
John Bridgeman, Manchester (GB); Robert Hawkins, Manchester (GB); Ruben Rodriguez, Dallas, TX (US); Sujita Sukumaran, Dallas, TX (US); Xingliang Zhou, Dallas, TX (US); and Eric Gschweng, Dallas, TX (US)
Assigned to INSTIL BIO (UK) LIMITED, Manchester (GB)
Filed by Instil Bio (UK) Limited, Manchester (GB)
Filed on Aug. 25, 2022, as Appl. No. 17/822,251.
Application 17/822,251 is a continuation in part of application No. PCT/US2022/073741, filed on Jul. 14, 2022.
Claims priority of provisional application 63/222,916, filed on Jul. 16, 2021.
Prior Publication US 2023/0059511 A1, Feb. 23, 2023
Int. Cl. C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/7051 (2013.01) [C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

25 Claims

1. A fusion protein comprising:

(a) a binding domain, wherein the binding domain comprises: an L-CDR1 sequence comprising the amino acid sequence of SEQ ID NO: 168, an L-CDR2 sequence comprising the amino acid sequence of SEQ ID NO: 169, an L-CDR3 sequence comprising the amino acid sequence of SEQ ID NO: 170, an H-CDR1 sequence comprising the amino acid sequence of SEQ ID NO: 171, an H-CDR2 sequence comprising the amino acid sequence of SEQ ID NO: 172, and an H-CDR3 sequence comprising the amino acid sequence of SEQ ID NO: 173;

(b) an amino acid sequence of SEQ ID NO: 162 linked to the binding domain;

(d) an amino acid sequence of SEQ ID NO: 164 linked to (c); and

(e) an amino acid sequence of SEQ ID NO: 165 linked to (d).